<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">In the context of the current coronavirus diseaseÂ 2019 (COVID-19) pandemic, physicians treating patients with immune-mediated dermatologic diseases are tasked with challenging decisions when initiating immunosuppressive therapy or altering the existing regimens of their patients. This article will examine relevant systemic drug safety data obtained from clinical trials, registries, and cohort studies across disciplines to provide expert-derived guidance in the face of much uncertainty.</p>
